Vasoactive drug therapies

Phase 3Small molecule

GGruppo Italiano Multidisciplinare per lo Studio della Sincope

Vasoactive drug therapies is one of 6 small molecule programs targeting Syncope. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SyncopeActive, not recruiting

SyncopePhase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Syncope

#DrugCompanyPhaseTrials

Inderal

WWyeth-Lederle Vaccines

Zofran

1 3

Vasoactive drug therapies

GGruppo Italiano Multidisciplinare per lo Studio della Sincope

Phase 3

1 4

Proamatine

Takeda

Preclinical

1 5

Theo-Dur

Pfizer

Preclinical

1 6

Adenocard

Astellas

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Syncope1 trial

Stop Vasodepressor Drugs in Reflex Syncope

Completed·GGruppo Italiano Multidisciplinare per lo Studio della Sincope·Phase 3·NCT02137278·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vasoactive drug therapies. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vasoactive drug therapies compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vasoactive drug therapies. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gruppo Italiano Multidisciplinare per lo Studio della Sincope company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGruppo Italiano Multidisciplinare per lo Studio della Sincope

Vasoactive drug therapies

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Syncope1 trial

References

Drug Info

Quick Facts

Related News